Literature DB >> 8399529

A sensitive radioimmunoassay, incorporating solid-phase extraction, for fluticasone 17-propionate in plasma.

B M Bain1, G Harrison, K D Jenkins, A J Pateman, E V Shenoy.   

Abstract

Antibodies were produced in rabbits immunized with fluticasone 17-propionate (FP) conjugated to bovine thyroglobulin via its 3-carboxymethoxime with isobutylchloroformate. The antibodies were used to develop a sensitive and specific radioimmunoassay (RIA) for FP in human plasma. The limit of quantitation of the RIA is 50 pg per assay tube. This translates to 50 pg ml-1 plasma when a solid-phase extraction preceded the RIA. The interassay and intraassay relative standard deviations were < 15% in the centre of the assay concentration range rising to < 25% at the lower and upper limits (50 and 250 pg ml-1). No appreciable binding was seen between the antibodies and the metabolite of FP that has been identified in man. The RIA was used to study the time course of plasma concentrations in man following inhalation of FP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8399529     DOI: 10.1016/0731-7085(93)80005-l

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  8 in total

1.  Bioavailability of orally administered micronised fluticasone propionate.

Authors:  C Falcoz; R Oliver; J E McDowall; P Ventresca; A Bye; P T Daley-Yates
Journal:  Clin Pharmacokinet       Date:  2000       Impact factor: 6.447

2.  Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma.

Authors:  P T Daley-Yates; J Tournant; R L Kunka
Journal:  Clin Pharmacokinet       Date:  2000       Impact factor: 6.447

3.  The relationship between systemic exposure to fluticasone propionate and cortisol reduction in healthy male volunteers.

Authors:  A E Mackie; A Bye
Journal:  Clin Pharmacokinet       Date:  2000       Impact factor: 6.447

4.  An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers.

Authors:  A Lönnebo; A Grahnén; B Jansson; R M Brundin; A Ling-Andersson; S A Eckernäs
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

5.  Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients.

Authors:  D J Clark; A Grove; R I Cargill; B J Lipworth
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

Review 6.  New perspectives on inhaled drug delivery and systemic bioactivity.

Authors:  B J Lipworth
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

7.  An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers.

Authors:  A Grahnén; S A Eckernäs; R M Brundin; A Ling-Andersson
Journal:  Br J Clin Pharmacol       Date:  1994-12       Impact factor: 4.335

8.  A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects.

Authors:  A Grove; C Allam; L C McFarlane; G McPhate; C M Jackson; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1994-12       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.